Different clinical and cytogenetic features of primary skull base meningiomas and non-skull base meningiomas.
Copy number variation
Degree of resection
Meningiomas
Recurrence
Skull base
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
29
04
2023
accepted:
22
05
2023
medline:
7
7
2023
pubmed:
2
6
2023
entrez:
2
6
2023
Statut:
ppublish
Résumé
To investigate the different clinical and cytogenetic features of skull base meningiomas (SBMs) and non-SBMs (NSBMs). We conducted a retrospective study on a series of 316 patients with primary intracranial meningiomas. The t-test and the Chi-square test were used to analyze the differences between 194 SBMs and 122 NSBMs. The Cox analysis was used to determine prognostic factors for tumor recurrence. Compared with NSBMs, on average, the age of patients with SBMs was about 2.88 years younger (p = 0.024); the duration of operation of SBMs was 2.73 h longer (p < 0.001); the duration of hospital stays of patients with SBMs was about 6.76 days longer (p < 0.001); the tumor volume was 7.69 cm The clinical and cytogenetic features of SBMs were different from NSBMs. Moreover, the degree of resection and the total number of whole-genome CNVs were independent prognostic factors for tumor recurrence.
Identifiants
pubmed: 37266847
doi: 10.1007/s11060-023-04351-1
pii: 10.1007/s11060-023-04351-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-453Subventions
Organisme : Natural Science Foundation of Beijing
ID : J180005,7192056
Organisme : National Key Research and Development Program of China
ID : 2022YFE0112500
Organisme : the Higher Education Discipline Innovation Project
ID : the 111 Project No. B13003
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Kruchko C, Ostrom QT, Gittleman H, Barnholtz-Sloan JS (2018) The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro Oncol 20:295–298. https://doi.org/10.1093/neuonc/noy006
doi: 10.1093/neuonc/noy006
pubmed: 29471448
pmcid: 5817957
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1
pubmed: 27157931
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, von Deimling A, Stavrinou P, Lefranc F, Lund-Johansen M, Moyal EC, Brandsma D, Henriksson R, Soffietti R, Weller M (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383–391. https://doi.org/10.1016/S1470-2045(16)30321-7
doi: 10.1016/S1470-2045(16)30321-7
pubmed: 27599143
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Johnson MD (2017) Transforming growth factor Beta family in the Pathogenesis of Meningiomas. World Neurosurg 104:113–119. https://doi.org/10.1016/j.wneu.2017.03.058
doi: 10.1016/j.wneu.2017.03.058
pubmed: 28344175
Mawrin C, Perry A (2010) Pathological classification and molecular genetics of meningiomas. J Neurooncol 99:379–391. https://doi.org/10.1007/s11060-010-0342-2
doi: 10.1007/s11060-010-0342-2
pubmed: 20809251
Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB Jr, Rhoton AL (1997) Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39:427–436. https://doi.org/10.1016/s0360-3016(97)00317-9
doi: 10.1016/s0360-3016(97)00317-9
pubmed: 9308947
Soyuer S, Chang EL, Selek U, Shi W, Maor MH, DeMonte F (2004) Radiotherapy after surgery for benign cerebral meningioma. Radiother Oncol 71:85–90. https://doi.org/10.1016/j.radonc.2004.01.006
doi: 10.1016/j.radonc.2004.01.006
pubmed: 15066300
Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, Curry WT Jr, Barker FG 2nd (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64:56–60 discussion 60. https://doi.org/10.1227/01.NEU.0000330399.55586.63
doi: 10.1227/01.NEU.0000330399.55586.63
pubmed: 19145156
Hug EB, Devries A, Thornton AF, Munzenride JE, Pardo FS, Hedley-Whyte ET, Bussiere MR, Ojemann R (2000) Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol 48:151–160
doi: 10.1023/A:1006434124794
pubmed: 11083080
Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M (1999) Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 110:103–110
doi: 10.1016/S0165-4608(98)00209-X
pubmed: 10214357
Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW (2002) A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12:183–190
pubmed: 11958372
Jansen M, Mohapatra G, Betensky RA, Keohane C, Louis DN (2012) Gain of chromosome arm 1q in atypical meningioma correlates with shorter progression-free survival. Neuropathol Appl Neurobiol 38:213–219. https://doi.org/10.1111/j.1365-2990.2011.01222.x
doi: 10.1111/j.1365-2990.2011.01222.x
pubmed: 21988727
pmcid: 3563294
Maillo A, Orfao A, Espinosa AB, Sayagues JM, Merino M, Sousa P, Lara M, Tabernero MD (2007) Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol 9:438–446. https://doi.org/10.1215/15228517-2007-026
doi: 10.1215/15228517-2007-026
pubmed: 17704362
pmcid: 1994101
Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Pestana A, Rey JA (1994) Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 9:296–298
doi: 10.1002/gcc.2870090411
pubmed: 7519053
McNulty SN, Schwetye K, Goldstein M, Carter J, Schmidt RE, Ansstas G, Tsien CI, Kim AH, Dahiya S (2018) Analysis of point mutations and copy number variation in Grade II and III meningioma. Exp Mol Pathol 105:328–333. https://doi.org/10.1016/j.yexmp.2018.10.007
doi: 10.1016/j.yexmp.2018.10.007
pubmed: 30316860
Olar A, Wani KM, Wilson CD, Zadeh G, DeMonte F, Jones DT, Pfister SM, Sulman EP, Aldape KD (2017) Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol 133:431–444. https://doi.org/10.1007/s00401-017-1678-x
doi: 10.1007/s00401-017-1678-x
pubmed: 28130639
pmcid: 5600514
Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S (2010) Genomic landscape of meningiomas. Brain Pathol 20:751–762. https://doi.org/10.1111/j.1750-3639.2009.00356.x
doi: 10.1111/j.1750-3639.2009.00356.x
pubmed: 20015288
Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekanne Dit Deprez R, Zwarthoff E (2001) NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 194:367–372. https://doi.org/10.1002/path.909
doi: 10.1002/path.909
pubmed: 11439370
Cornelius JF, Slotty PJ, Steiger HJ, Hanggi D, Polivka M, George B (2013) Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases. Acta Neurochir (Wien) 155:407–413. https://doi.org/10.1007/s00701-012-1611-y
doi: 10.1007/s00701-012-1611-y
pubmed: 23318687
Kane AJ, Sughrue ME, Rutkowski MJ, Shangari G, Fang S, McDermott MW, Berger MS, Parsa AT (2011) Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer 117:1272–1278. https://doi.org/10.1002/cncr.25591
doi: 10.1002/cncr.25591
pubmed: 21381014
Sade B, Chahlavi A, Krishnaney A, Nagel S, Choi E, Lee JH (2007) World Health Organization Grades II and III meningiomas are rare in the cranial base and spine. Neurosurgery 61:1194–1198 discussion 1198. https://doi.org/10.1227/01.neu.0000306097.38141.65
doi: 10.1227/01.neu.0000306097.38141.65
pubmed: 18162898
Meling TR, Da Broi M, Scheie D, Helseth E (2019) Skull base versus non-skull base meningioma surgery in the elderly. Neurosurg Rev 42:961–972. https://doi.org/10.1007/s10143-018-1005-6
doi: 10.1007/s10143-018-1005-6
pubmed: 29978438
Magill ST, Young JS, Chae R, Aghi MK, Theodosopoulos PV, McDermott MW (2018) Relationship between tumor location, size, and WHO grade in meningioma. Neurosurg Focus 44:E4. https://doi.org/10.3171/2018.1.FOCUS17752
doi: 10.3171/2018.1.FOCUS17752
pubmed: 29606048
Lemee JM, Corniola MV, Da Broi M, Joswig H, Scheie D, Schaller K, Helseth E, Meling TR (2019) Extent of Resection in Meningioma: predictive factors and clinical implications. Sci Rep 9:5944. https://doi.org/10.1038/s41598-019-42451-z
doi: 10.1038/s41598-019-42451-z
pubmed: 30976047
pmcid: 6459829
Ma J, Hong Y, Chen W, Li D, Tian K, Wang K, Yang Y, Zhang Y, Chen Y, Song L, Chen L, Zhang L, Du J, Zhang J, Wu Z, Zhang D, Wang L (2020) High Copy-Number variation Burdens in cranial Meningiomas from patients with diverse clinical phenotypes characterized by hot genomic structure changes. Front Oncol 10:1382. https://doi.org/10.3389/fonc.2020.01382
doi: 10.3389/fonc.2020.01382
pubmed: 32923390
pmcid: 7457130
Kong CC, Kandasamy R, Haspani S, Idris Z, Abdullah JM (2018) Incidence, clinico-radiological features and outcome of Skull Base versus Non-Skull Base Meningiomas treated in Kuala Lumpur General Hospital: a five-year experience. Malays J Med Sci 25:88–102. https://doi.org/10.21315/mjms2018.25.3.9
doi: 10.21315/mjms2018.25.3.9
pubmed: 30899190
pmcid: 6422556
Lagman C, Ong V, Nguyen T, Alkhalid Y, Sheppard JP, Romiyo P, Azzam D, Prashant GN, Jahan R, Yang I (2018) The Meningioma Vascularity Index: a volumetric analysis of flow voids to predict intraoperative blood loss in nonembolized meningiomas. J Neurosurg 1–6. https://doi.org/10.3171/2018.1.JNS172724
Ghodrati F, Mekonnen M, Mahgerefteh N, Zhang AB, Pradhan A, Mozaffari K, Duong C, Yang I (2023) Preoperative meningioma vascularity index is associated with significantly increased intraoperative blood loss and greater risk of subtotal resection. J Neurooncol 161:583–591. https://doi.org/10.1007/s11060-023-04259-w
doi: 10.1007/s11060-023-04259-w
pubmed: 36786952
Voss KM, Spille DC, Sauerland C, Suero Molina E, Brokinkel C, Paulus W, Stummer W, Holling M, Jeibmann A, Brokinkel B (2017) The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value? J Neurooncol 133:641–651. https://doi.org/10.1007/s11060-017-2481-1
doi: 10.1007/s11060-017-2481-1
pubmed: 28527009
McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY (2010) A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg 112:925–933. https://doi.org/10.3171/2009.9.JNS09617
doi: 10.3171/2009.9.JNS09617
pubmed: 19799498
Lagman C, Sheppard JP, Beckett JS, Tucker AM, Nagasawa DT, Prashant GN, Ziman A, Yang I (2018) Red blood cell transfusions following resection of Skull Base Meningiomas: risk factors and clinical outcomes. J Neurol Surg B Skull Base 79:599–605. https://doi.org/10.1055/s-0038-1651502
doi: 10.1055/s-0038-1651502
pubmed: 30456031
pmcid: 6239878
Nanda A, Bir SC, Maiti TK, Konar SK, Missios S, Guthikonda B (2017) Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma. J Neurosurg 126:201–211. https://doi.org/10.3171/2016.1.JNS151842
doi: 10.3171/2016.1.JNS151842
pubmed: 27058201
Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V, Greenwald NF, Nassiri F, Aldape K, Zadeh G, Choudhury A, Vasudevan HN, Magill ST, Raleigh DR, Abedalthagafi M, Aizer AA, Alexander BM, Ligon KL, Reardon DA, Wen PY, Al-Mefty O, Ligon AH, Dubuc AM, Beroukhim R, Claus EB, Dunn IF, Santagata S, Linda Bi W (2022) A molecularly integrated grade for meningioma. Neuro Oncol 24:796–808. https://doi.org/10.1093/neuonc/noab213
doi: 10.1093/neuonc/noab213
pubmed: 34508644
Maas SLN, Stichel D, Hielscher T, Sievers P, Berghoff AS, Schrimpf D, Sill M, Euskirchen P, Blume C, Patel A, Dogan H, Reuss D, Dohmen H, Stein M, Reinhardt A, Suwala AK, Wefers AK, Baumgarten P, Ricklefs F, Rushing EJ, Bewerunge-Hudler M, Ketter R, Schittenhelm J, Jaunmuktane Z, Leu S, Greenway FEA, Bridges LR, Jones T, Grady C, Serrano J, Golfinos J, Sen C, Mawrin C, Jungk C, Hanggi D, Westphal M, Lamszus K, Etminan N, Jungwirth G, Herold-Mende C, Unterberg A, Harter PN, Wirsching HG, Neidert MC, Ratliff M, Platten M, Snuderl M, Aldape KD, Brandner S, Hench J, Frank S, Pfister SM, Jones DTW, Reifenberger G, Acker T, Wick W, Weller M, Preusser M, von Deimling A, Sahm F (2021) Integrated Molecular-Morphologic Meningioma classification: a Multicenter Retrospective Analysis, retrospectively and prospectively validated. J Clin Oncol 39:3839–3852 German Consortium on Aggressive. https://doi.org/10.1200/JCO.21.00784
doi: 10.1200/JCO.21.00784
pubmed: 34618539
pmcid: 8713596
Mansouri A, Klironomos G, Taslimi S, Kilian A, Gentili F, Khan OH, Aldape K, Zadeh G (2016) Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. J Neurosurg 125:431–440. https://doi.org/10.3171/2015.7.JNS15546
doi: 10.3171/2015.7.JNS15546
pubmed: 26722844
Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V, Greenwald NF, Nassiri F, Aldape K, Zadeh G, Choudhury A, Vasudevan HN, Magill ST, Raleigh DR, Abedalthagafi M, Aizer AA, Alexander BM, Ligon KL, Reardon DA, Wen PY, Al-Mefty O, Ligon AH, Dubuc AM, Beroukhim R, Claus EB, Dunn IF, Santagata S, Bi WL (2022) A molecularly integrated grade for meningioma. Neuro Oncol 24:796–808. https://doi.org/10.1093/neuonc/noab213
doi: 10.1093/neuonc/noab213
pubmed: 34508644
Aizer AA, Abedalthagafi M, Bi WL, Horvath MC, Arvold ND, Al-Mefty O, Lee EQ, Nayak L, Rinne ML, Norden AD, Reardon DA, Wen PY, Ligon KL, Ligon AH, Beroukhim R, Dunn IF, Santagata S, Alexander BM (2016) A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol 18:269–274. https://doi.org/10.1093/neuonc/nov177
doi: 10.1093/neuonc/nov177
pubmed: 26323607
Gousias K, Schramm J, Simon M (2016) The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J Neurosurg 125:551–560. https://doi.org/10.3171/2015.9.JNS15754
doi: 10.3171/2015.9.JNS15754
pubmed: 26824369
Zhang GJ, Zhang YS, Zhang GB, Yan XJ, Li CB, Zhang LW, Li D, Wu Z, Zhang JT (2018) Prognostic factors, survival, and treatment for Intracranial World Health Organization Grade II Chordoid Meningiomas and clear-cell meningiomas. World Neurosurg 117:e57–e66. https://doi.org/10.1016/j.wneu.2018.04.226
doi: 10.1016/j.wneu.2018.04.226
pubmed: 29859361
Masalha W, Heiland DH, Franco P, Delev D, Haaker JG, Schnell O, Scheiwe C, Grauvogel J (2018) Atypical meningioma: progression-free survival in 161 cases treated at our institution with surgery versus surgery and radiotherapy. J Neurooncol 136:147–154. https://doi.org/10.1007/s11060-017-2634-2
doi: 10.1007/s11060-017-2634-2
pubmed: 29081038
Jiang Y, Lv L, Li J, Ma W, Chen C, Zhou P, Jiang S (2020) Clinical features, radiological findings, and treatment outcomes of high-grade lateral ventricular meningiomas: a report of 26 cases. Neurosurg Rev 43:565–573. https://doi.org/10.1007/s10143-019-01078-4
doi: 10.1007/s10143-019-01078-4
pubmed: 30649647
Ma XJ, Zhang GJ, Wang W, Li D, Wu Z, Zhang JT (2019) Proposed treatment for intracranial transitional meningioma: a Single-Center Series of 298 cases. World Neurosurg 127:e280–e287. https://doi.org/10.1016/j.wneu.2019.03.104
doi: 10.1016/j.wneu.2019.03.104
pubmed: 30902770
Wang C, Kaprealian TB, Suh JH, Kubicky CD, Ciporen JN, Chen Y, Jaboin JJ (2017) Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma. Neuro Oncol 19:1263–1270. https://doi.org/10.1093/neuonc/nox007
doi: 10.1093/neuonc/nox007
pubmed: 28371851
pmcid: 5570224
Domingues PH, Sousa P, Otero A, Goncalves JM, Ruiz L, de Oliveira C, Lopes MC, Orfao A, Tabernero MD (2014) Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol 16:735–747. https://doi.org/10.1093/neuonc/not325
doi: 10.1093/neuonc/not325
pubmed: 24536048
pmcid: 3984558
Ketter R, Henn W, Niedermayer I, Steilen-Gimbel H, Konig J, Zang KD, Steudel WI (2001) Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. J Neurosurg 95:601–607. https://doi.org/10.3171/jns.2001.95.4.0601
doi: 10.3171/jns.2001.95.4.0601
pubmed: 11596954